(2S)-2-[[9-[(2S,3R,4S,5R)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]嘌呤-6-基]氨基]丁二酸 | 4542-23-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: (2S)-2-[[9-[(2S,3R,4S,5R)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]嘌呤-6-基]氨基]丁二酸
• 英文名称: (2S)-2-[[9-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid
• CAS: 4542-23-8
• 化学式: C₁₄H₁₇N₅O₈
• 分子量: 383.31
• InChiKey: VKGZCEJTCKHMRL-MDBUBQOGSA-N

物化性质

• 熔点：
  >180°C (dec.)
• 沸点：
  816.4±75.0 °C(Predicted)
• 密度：
  2.02±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  200
• 氢给体数：
  6
• 氢受体数：
  12

制备方法与用途

生物活性

Succinyladenosine（S-腺苷酸）是胞内腺苷酸（S-AMP）经5-核苷酸酶脱磷酸化的产物，也是腺苷酸琥珀酸酶（ASL）缺乏的生化标志。

靶点

Human Endogenous Metabolite

体外研究

在人类脑脊液（CSF）中高浓度的Succinyladenosine (S-Ado)（范围为100–500 μmol/L）是ASL遗传缺陷引起的酶缺乏症的诊断标志。

用途

Succinyladenosine (S-Ado) 是腺苷酸琥珀酸酶缺乏症——嘧啶从头合成基因缺陷的一种生物化学标志。此前有报道，未患此病的儿童脑脊液（CSF）中通常检测不到 S-Ado。

文献信息

• MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
  申请人：Universität Basel

  公开号：EP3889602A1

  公开（公告）日：2021-10-06

  The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a eukaryotic cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.

  本发明涉及一种调节MR1多肽与MR1特异性T细胞受体分子之间相互作用的方法，其中MR1多肽与MR1配体化合物接触，MR1配体化合物是反映真核细胞代谢窘迫状态的核碱基加合物产物。 本发明进一步涉及鉴定为 MR1 配体的化合物在疫苗接种或调节 MR1 限制性免疫反应中的用途。
• Detection and Quantitation Method for Proteomics of Post-Translational Modifications
  申请人：Sichuan University

  公开号：US20200033361A1

  公开（公告）日：2020-01-30

  The present disclosure relates to the technical field of comparative proteomics, in particular to a detection and quantitation method for proteomics of post-translational modifications. With this method, the protein samples to be studied and internal standards are labeled with isobaric tandem mass tags, and tandem mass spectrometry analysis is carried out for the labeled peptide mixture, wherein the internal standard is a peptide mixture rich in post-translational modifications to be detected. Through this method, the signal of peptides containing the post-translational modifications to be detected can be amplified under the situation that mass spectrometer sensitivity is unchanged, and enrichment of the post-translational modification peptides is not needed. The probability of detecting the peptides containing the post-translational modifications to be detected by mass spectrometer and being selected for subsequent MS/MS analysis is increased.
• [EN] MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION<br/>[FR] LIGANDS MR1 ET COMPOSITIONS PHARMACEUTIQUES POUR IMMUNOMODULATION
  申请人：UNIV BASEL

  公开号：WO2021144475A1

  公开（公告）日：2021-07-22

  The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.